Safety, pharmacokinetics and pharmacodynamics of BI 655064 in phase 1 clinical trials in healthy Chinese and Japanese subjects-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Safety, pharmacokinetics and pharmacodynamics of BI 655064 in phase 1 clinical trials in healthy Chinese and Japanese subjects

Published:2020-12-09 Issue:4 Volume:87 Page:2000-2013
ISSN:0306-5251
Container-title:British Journal of Clinical Pharmacology
language:en
Short-container-title:Br J Clin Pharmacol

Author:

Tsuda Yasuhiro¹,Grimaldi Christine²,Huang Fenglei²,Benediktus Ewald³,Yagi Nobutaka⁴,Padula Steven J.⁵,Jang In‐Jin⁶,Steffgen Jürgen⁷

Affiliation:

1. Nippon Boehringer Ingelheim Co. Ltd Kobe Japan

2. Boehringer Ingelheim Pharmaceuticals Inc. Ridgefield CT USA

3. Boehringer Ingelheim Pharma GmbH & Co. KG Biberach Germany

4. Nippon Boehringer Ingelheim Co. Ltd Tokyo Japan

5. Boehringer Ingelheim International GmbH Ingelheim Germany

6. Seoul National University Hospital Clinical Trials Center Seoul Korea

7. Boehringer Ingelheim International GmbH Biberach Germany

Funder

Boehringer Ingelheim

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bcp.14601

Reference30 articles.

1. Identification and Characterization of Post-activated B Cells in Systemic Autoimmune Diseases

2. Treatment with a CD40 Antagonist Antibody Reverses Severe Proteinuria and Loss of Saliva Production and Restores Glomerular Morphology in Murine Systemic Lupus Erythematosus

3. Effects of BI 655064, an antagonistic anti-CD40 antibody, on clinical and biomarker variables in patients with active rheumatoid arthritis: a randomised, double-blind, placebo-controlled, phase IIa study

4. B Cell Abnormalities in Systemic Lupus Erythematosus and Lupus Nephritis—Role in Pathogenesis and Effect of Immunosuppressive Treatments

5. Lupus Nephritis in Asia: Clinical Features and Management

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Lupus Nephritis: Improving Treatment Options;Drugs;2022-04-29

2. CD40–CD40L in Neurological Disease;International Journal of Molecular Sciences;2022-04-08

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3